A
Amy Hauck Newman
Researcher at National Institute on Drug Abuse
Publications - 302
Citations - 12937
Amy Hauck Newman is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine transporter & Dopamine. The author has an hindex of 54, co-authored 282 publications receiving 11666 citations. Previous affiliations of Amy Hauck Newman include National Institutes of Health & Uniformed Services University of the Health Sciences.
Papers
More filters
Journal ArticleDOI
Structure of the human dopamine d3 receptor in complex with a d2/d3 selective antagonist.
Ellen Y.T. Chien,Wei Liu,Qiang Zhao,Vsevolod Katritch,Gye Won Han,Michael A. Hanson,Lei Shi,Amy Hauck Newman,Jonathan A. Javitch,Vadim Cherezov,Raymond C. Stevens +10 more
TL;DR: The crystal structure of the human dopamine D3 receptor in complex with the small molecule D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.
Journal ArticleDOI
Genetic basis for species vulnerability in the Cheetah
Stephen J. O'Brien,Melody E. Roelke,Laurie Marker,Amy Hauck Newman,Cheryl A. Winkler,D. G. Meltzer,L. Colly,James F. Evermann,Mitchell Bush,David E. Wildt +9 more
TL;DR: The extreme genetic monomorphism, especially at the major histocompatibility complex, and the apparent hypersensitivity of the cheetah to a viral pathogen may be related, provide a biological basis for understanding the adaptive significance of abundant genetic variation in outbred mammalian species.
Journal ArticleDOI
The binding sites for cocaine and dopamine in the dopamine transporter overlap
Thijs Beuming,Julie Kniazeff,Marianne L. Bergmann,Lei Shi,Luis Gracia,Klaudia Raniszewska,Amy Hauck Newman,Jonathan A. Javitch,Harel Weinstein,Ulrik Gether,Claus J. Loland +10 more
TL;DR: The models suggest that the binding site for cocaine and cocaine analogs is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrates dopamine and amphetamine, as well as for benztropine-like DAT inhibitors.
Journal ArticleDOI
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues
Laura Albizu,Martin Cottet,Martin Cottet,Martin Cottet,Michaela Kralikova,Stoytcho Stoev,René Seyer,René Seyer,René Seyer,Isabelle Brabet,Isabelle Brabet,Isabelle Brabet,Thomas Roux,Herve Bazin,Emmanuel Bourrier,Laurent Lamarque,Christophe Breton,Marie-Laure Rives,Amy Hauck Newman,Jonathan A. Javitch,Eric Trinquet,Maurice Manning,Jean-Philippe Pin,Jean-Philippe Pin,Jean-Philippe Pin,Bernard Mouillac,Bernard Mouillac,Bernard Mouillac,Thierry Durroux,Thierry Durroux,Thierry Durroux +30 more
TL;DR: A time-resolved FRET strategy based on receptor labeling with selective fluorescent ligands was developed and applied to native tissues and succeeded in demonstrating the presence of oxytocin receptor dimers and/or oligomers in mammary gland.
Journal ArticleDOI
Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
TL;DR: Preclinical evidence in support of the efficacy of selective DA D3 receptor antagonists in animal models of drug addiction will be reviewed and translational research from preclinical efficacy studies to so‐called proof‐of‐concept studies for drug addiction indications will be discussed.